share_log

汇宇制药(688553.SH):注射用阿扎胞苷、注射用盐酸苯达莫司汀获得乌兹别克斯坦上市许可

Huiyu Pharmaceutical (688553.SH): Azacitidine for injection and bendamustine hydrochloride for injection obtained marketing approval in Uzbekistan

Gelonghui Finance ·  Aug 7 04:50

On August 7th, Gelunhui reported that Huayu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary, Seacross Pharmaceuticals Ltd., recently received approval from the Uzbekistan Drug Administration for the marketing of the company's injectable azacitidine and injectable pandomitin hydrochloride. Azacitidine for injection is a nucleoside analogue of cytidine, which produces antitumor effects by causing DNA demethylation and direct cytotoxic effects on abnormal hematopoietic cells in the bone marrow. Injectable pandomitin hydrochloride is used for first-line treatment of chronic lymphocytic leukemia (Binet stage B or C) patients who are not suitable for fludarabine combination chemotherapy, single-agent treatment of indolent non-Hodgkin's lymphoma patients who experience progression during or within 6 months after treatment with rituximab or rituximab-containing regimens, and first-line treatment of multiple myeloma (Durie-Salmon stage II progression or stage III) patients who are over 65 years of age, do not meet the conditions for autologous stem cell transplantation, and have clinical neurological lesions at the time of diagnosis.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment